Cas no 1246646-23-0 (Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate)
Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate Chemical and Physical Properties
Names and Identifiers
-
- tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate
- tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate
- tert-butyl 4-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate
- Spiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylic acid, 2'-oxo-, 1,1-dimethylethyl ester
- AKOS037647424
- AS-73601
- 1246646-23-0
- tert-Butyl2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate
- WZB64623
- CS-WAA0062
- CS-0035409
- Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate
-
- MDL: MFCD18083843
- Inchi: 1S/C14H22N2O3/c1-13(2,3)19-12(18)16-9-4-5-10(16)7-14(6-9)8-15-11(14)17/h9-10H,4-8H2,1-3H3,(H,15,17)
- InChI Key: GKQNSWIQQQHWOO-UHFFFAOYSA-N
- SMILES: O=C1C2(CN1)CC1CCC(C2)N1C(=O)OC(C)(C)C
Computed Properties
- Exact Mass: 266.16304257 g/mol
- Monoisotopic Mass: 266.16304257 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 19
- Rotatable Bond Count: 2
- Complexity: 413
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 2
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 1.1
- Topological Polar Surface Area: 58.6
- Molecular Weight: 266.34
Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| eNovation Chemicals LLC | D773637-50mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 50mg |
$680 | 2024-06-06 | |
| eNovation Chemicals LLC | D773637-100mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 100mg |
$1090 | 2024-06-06 | |
| eNovation Chemicals LLC | D773637-200mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 200mg |
$1540 | 2024-06-06 | |
| Chemenu | CM476225-50mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 95%+ | 50mg |
$675 | 2023-01-10 | |
| Chemenu | CM476225-100mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 95%+ | 100mg |
$1080 | 2023-01-10 | |
| Chemenu | CM476225-250mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 95%+ | 250mg |
$1725 | 2023-01-10 | |
| 1PlusChem | 1P01CDAT-50mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 50mg |
$686.00 | 2024-07-10 | |
| 1PlusChem | 1P01CDAT-100mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 100mg |
$1085.00 | 2024-07-10 | |
| 1PlusChem | 1P01CDAT-200mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 200mg |
$1524.00 | 2024-07-10 | |
| Aaron | AR01CDJ5-50mg |
tert-butyl 2'-oxospiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-8-carboxylate |
1246646-23-0 | 97% | 50mg |
$609.00 | 2025-02-10 |
Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate Related Literature
-
Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
-
Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
-
Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
-
Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
-
Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
Additional information on Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate
Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate (CAS No. 1246646-23-0): A Comprehensive Overview
Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate, identified by its CAS number 1246646-23-0, is a structurally complex compound that has garnered significant attention in the field of medicinal chemistry and pharmacology. This spirocyclic derivative features a unique combination of heterocyclic and carbonyl functionalities, making it a promising candidate for further exploration in drug discovery and therapeutic applications.
The molecular structure of Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate incorporates an azaspiro framework, which is known for its potential to interact with biological targets in a highly specific manner. The presence of a tert-butyl group at the carboxyl position enhances the compound's lipophilicity, potentially improving its membrane permeability and bioavailability. These structural characteristics make it an intriguing molecule for designing novel therapeutic agents.
Recent advancements in computational chemistry and molecular modeling have enabled researchers to gain deeper insights into the interactions of Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate with biological targets. Studies have shown that the spirocyclic core can mimic the conformational flexibility of natural products, thereby increasing the likelihood of binding to specific enzymes or receptors. This property is particularly valuable in the development of small-molecule inhibitors for therapeutic purposes.
In addition to its structural advantages, Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate has demonstrated potential in various preclinical studies. Research has highlighted its ability to modulate key biological pathways associated with inflammation, cancer, and neurodegenerative diseases. For instance, preliminary data suggest that this compound may interfere with the activity of certain kinases involved in cell proliferation and survival, making it a candidate for further investigation in oncology research.
The synthesis of Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate presents both challenges and opportunities for synthetic chemists. The spirocyclic framework requires precise control over reaction conditions to ensure high yield and purity. However, recent methodologies involving transition metal catalysis and asymmetric synthesis have improved the efficiency of its preparation, opening doors for large-scale production and further derivatization.
The pharmacokinetic properties of Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate are also of considerable interest. Studies have begun to explore its metabolic stability and excretion pathways, which are critical factors in determining its clinical efficacy and safety profile. Advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy have been employed to characterize its degradation products and metabolic intermediates.
The potential applications of Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate extend beyond traditional pharmaceuticals. Researchers are exploring its use in agrochemicals and material science due to its unique structural features and chemical properties. For example, derivatives of this compound may exhibit herbicidal or fungicidal activity when incorporated into crop protection formulations.
As our understanding of molecular interactions continues to evolve, the role of compounds like Tert-butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate in drug discovery is likely to expand further. Collaborative efforts between chemists, biologists, and clinicians will be essential in translating these findings into tangible therapeutic benefits for patients worldwide.
1246646-23-0 (Tert-Butyl 2-oxo-8'-azaspiro[azetidine-3,3'-bicyclo[3.2.1]octane]-8'-carboxylate) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)